ISSUE NO. 41 — Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities

Immunomodulatory drugs are at the forefront for the treatment of various types of cancer, infectious diseases, and numerous autoimmune diseases, including rheumatoid arthritis, type I diabetes, lupus, and multiple sclerosis. As the complexity of these therapeutics increases, so must the sophistication of the bioanalytical assays designed to either quantify them or measure their impact on the patient. 

In Issue 41 of The Altascientist, we explore common classes of immunomodulators, bioanalytical methods used to quantify them, and their associated biomarkers. Featuring two scenarios that explore the complexities of bioanalysis for immunomodulators, The Altascientist offers practical considerations for ensuring accurate bioanalysis, as well as pharmacokinetic, pharmacodynamic, and safety data in clinical trials.

This issue also covers: 

• classes of immunomodulators, including monoclonal antibodies, CAR-T cells, and vaccines;
• immunotherapy trials, focusing on complex study designs and diverse patient populations; and

• bioanalytical methods and assays, including pharmacokinetics and anti-drug antibodies (ADA).

   

Immunomodulation Assessments for Clinical Trials

Immunomodulators can be broadly defined as immunostimulants and immunosuppressants, with many types of modalities. The growing understanding of the immune system's role in various diseases, along with advancements in drug development, have led to a natural evolution from traditional vaccines, small molecules, and cytokines, to increased targeted biologics and innovative approaches in gene therapy and vaccines. 

“Each class of immunomodulator has a defined complexity and mechanism of action. Thus, the appropriate bioanalytical program will need to be carefully designed for the drug type and the intended purpose of the clinical study." –The Altascientist, Issue 41 pg. 2

This includes careful consideration of pharmacokinetic and pharmacodynamic endpoints, as well as regulatory and bioanalytical requirements. 

Particular attention is needed for monoclonal antibodies, CAR-T cells, antibody-drug conjugates (ADCs), and vaccines, as each class requires tailored strategies to support clinical studies and ensure accurate data collection.

Explore all issues of The Altascientist in our Resource Center. And don’t forget to subscribe to The Altascientist: Audiobooks on Spotify, Apple Podcasts, or wherever you get your audio content.